EA-2351 a molecule that could potentially enable AMD patients to regain some of their lost vision
Channel: Endogena Therapeutics
Date: 2022-12-27

You may have noticed that a lot of people will start losing their vision as they get older. A common cause of this is AMD - Age-Related Macular Degeneration. By the age of 80, nearly one third of us will have this condition.

AMD affects the back of the eye, the macula, where the common type known as “dry AMD” causes the death of retinal pigment epithelial cells or RPE, forming wounds in areas where cells die. RPE cells are necessary for vision. As the wounds grow bigger, more and more vision is lost. AMD progression is irreversible because the eye stops generating new RPE cells once you are born.

Our vision at Endogena Therapeutics is to stop AMD progression and to regrow new healthy RPE cells. 

Using artificial intelligence, our scientists have discovered EA-2351, a molecule that when injected in the eye, reactivates RPE cell renewal for wound repair. Activated cells will then move to the areas where RPE cells have died due to AMD, will settle there, and develop into new healthy RPE. Preventing the wounds from getting bigger and promoting healing. This could potentially enable AMD patients to regain some of their lost vision.

Endogena’s treatment is different from other AMD treatments as it makes your own body produce new healthy cells. Our treatment does not require gene editing or injecting foreign cells into the body. 

Based on the same novel regenerative concept, we are currently testing a different molecule in patients with Retinitis Pigmentosa – a rare degenerative eye disease. Applying the same principles, we hope to help millions of AMD patients regain their vision.

More info
(info@endogena.com)

Explore more about Endogena Therapeutics
(http://endogena.com/)

#EndogenaTherapeutics #RegenerativeMedicine #DryAMD #StemCell #Ophthalmology #Eyes #Vision #VisionLoss #Blindness